ACER News and Press, Acer Therapeutics Inc. From 07/08/22

Gainers: MyMD Pharmaceuticals ( MYMD ) +23% . Clovis Oncology ( CLVS ) +22% . iRhythm Technologies ( IRTC ) +22% . Acer Therapeutics ( ACER ) +15% . Atreca ( BCEL ) +12% . Losers: RAPT Therapeutics ( RAPT ) -9% ...

NEWTON, Mass. and GENEVA, July 08, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), today announced that the China National Intellectual Property Administration (CNIP...

Acer Therapeutics (NASDAQ:ACER) said on Monday it had begun patient screening in its Phase 3 trial of Edsivo to treat patients with COL3A1-positive vascular Ehlers-Danlos Syndrome (vEDS), a rare genetic disorder that can cause blood vessels to fatally rupture. The main goal of the trial ...

NEWTON, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, tod...

Gainers: Convey Health Solutions Holdings (CNVY) +139%. Valneva (VALN) +86%. Green Giant (GGE) +78%. CEA Industries (CEAD) +76%. Clovis Oncology (CLVS) +71%. Tabula Rasa HealthCare (TRHC) +34%. Revlon (REV) +34%. Innate Pharma (IPHA) +33%. Sorrento Therapeutics (SRNE) +28%. MacroGenics (MGNX)...

Acer Therapeutics (NASDAQ:ACER) and partner Relief Therapeutics (OTCQB:RLFTF) said on Tuesday that the U.S. Food and Drug Administration declined to approve its drug, ACER-001, to treat patients with urea cycle disorders, rare genetic conditions primarily diagnosed in children....

Acer Therapeutics (NASDAQ:ACER) has named Tanya Hayden to succeed Harry S. Palmin as Chief Operating Officer (COO). Harry S. Palmin, who had been serving as the company’s Chief Operating Officer as well as its Chief Financial Officer, will continue to serve as Chief Financial Offi...

NEWTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced th...

Citing the need to inspect a third-party contract packaging manufacturer, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) The FDA has not raised any approvability concerns related to the efficacy, safety or pharmacokinetics of ACER-001...

Acer Therapeutics (NASDAQ:ACER) said the U.S. Food and Drug Administration (FDA) has not yet made a decision on its application for ACER-001 seeking approval of the drug for urea cycle disorders (UCDs). The FDA had accepted the company's new drug application (NDA) for review on...